Efficacy of Sulforaphane in Treatment of Children with Autism Spectrum Disorder: A Randomized Double-Blind Placebo-Controlled Multi-center Trial.
Autor: | Ou J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Smith RC; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.; Department of Psychiatry, New York University School of Medicine, New York, NY, USA., Tobe RH; Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.; Department of Psychiatry, Columbia University, New York, NY, USA., Lin J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Arriaza J; School of Professional Studies, New York University, New York, NY, USA., Fahey JW; Departments of Medicine, Psychiatry and Behavioral Sciences, and Pharmacology & Molecular Sciences, Johns Hopkins University, Baltimore, MD, USA., Liu R; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Zeng Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Liu Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Huang L; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Shen Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Li Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China., Cheng D; The Affiliated Brain Hospital of Guangzhou Medical University, Guangzhou, 510370, Guangdong, China., Cornblatt B; Nutramax Laboratories, Consumer Care, Inc., Edgewood, MD, USA., Davis JM; Department of Psychiatry, University of Illinois, Psychiatric Institute, Chicago, IL, USA., Zhao J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China. zhaojingping@csu.edu.cn.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China. zhaojingping@csu.edu.cn.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China. zhaojingping@csu.edu.cn.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China. zhaojingping@csu.edu.cn., Wu R; Department of Psychiatry, National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Middle Renmin Road, Changsha, 410011, Hunan, China. wurenrong@csu.edu.cn.; Hunan Medical Center for Mental Health, Changsha, 410011, Hunan, China. wurenrong@csu.edu.cn.; China National Technology Institute on Mental Disorders, Changsha, 410011, Hunan, China. wurenrong@csu.edu.cn.; Hunan Key Laboratory of Psychiatry and Mental Health, Changsha, 410011, Hunan, China. wurenrong@csu.edu.cn.; Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, 200031, China. wurenrong@csu.edu.cn., Jin H; Department of Psychiatry, University of California San Diego and Psychiatric Service, VA San Diego Healthcare System, San Diego, CA, USA. hjin@health.ucsd.edu. |
---|---|
Jazyk: | angličtina |
Zdroj: | Journal of autism and developmental disorders [J Autism Dev Disord] 2024 Feb; Vol. 54 (2), pp. 628-641. Date of Electronic Publication: 2022 Nov 24. |
DOI: | 10.1007/s10803-022-05784-9 |
Abstrakt: | Sulforaphane has been reported to possibly improve core symptoms associated with autism spectrum disorders from mostly small size studies. Here we present results of a larger randomized clinical trial (N = 108) in China. There were no significant changes in caregiver rated scales between sulforaphane and placebo groups. However, clinician rated scales showed a significant improvement in the sulforaphane group, and one third of participants showed at least a 30% decrease in score by 12 weeks treatment. The effects of sulforaphane were seen across the full range of intelligence and greater in participants over 10 years. Sulforaphane was safe and well-tolerated even for young children. The inconsistent results between caregiver and clinician rated scales suggest more clinical trials are needed to confirm our findings. (© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.) |
Databáze: | MEDLINE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |